Binding of ciprofloxacin labelled with technetium Tc 99m versus 99mTc-pertechnetate to a live and killed equine isolate of escherichia coli

Canadian Journal of Veterinary Research

Volumn 69, Issue 4, 2005, Pages 272-277

  Alexander, Kate ^a,b   Drost, Wm Tod ^a   Mattoon, John S ^a   Kowalski, Joseph J ^a   Funk, Julie A ^a   Crabtree, Amanda C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; INFECTON; PERTECHNETIC ACID TC 99M; TECHNETIUM 99M; WATER;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BINDING; DRUG LABELING; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HORSE; INCUBATION TIME; METHODOLOGY; NONHUMAN; RADIOACTIVITY; SUPERNATANT;

ANIMALS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HORSE DISEASES; HORSES; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SODIUM PERTECHNETATE TC 99M; TIME FACTORS;

BACTERIA (MICROORGANISMS); ENTEROBACTER; EQUIDAE; EQUUS CABALLUS; ESCHERICHIA COLI;

EID: 28444490279     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hertzberg RP. Agents interfering with nucleic acids. In: Hansch C, Sammes PG, Taylor JB, eds. Comprehensive Medicinal Chemistry: the Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds. New York: Pergamon Press, 1990:753-791.
2. Petri WA. Antimicrobial agents: sulfonamides, trimethoprim-sulfamethoxazole, quinolones. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. Chicago: McGraw-Hill, 2001.
3. Yapar Z, Kibar M, Yapar AF, Togrul E, Kayaselcuk U, Sarpel Y. The efficacy of technetium-99m ciprofloxacin (Infecton) imaging in suspected orthopaedic infection: a comparison with sequential bone/gallium imaging. Eur J Nucl Med 2001;28: 822-830.
4. Vinjamuri S, Hall AV, Solanki KK, et al. Comparison of 99mTc Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996;347: 233-235.
5. Sundram FX, Wong WY, Ang ES, Goh AS, Ng DC, Yu S. Evaluation of technetium-99m ciprofloxacin (Infecton) in the imaging of infection. Ann Acad Med Singapore 2000;29: 699-703.
6. Southwood LL, Kawcak CE, McIlwraith CW, Frisbie DD, Steyn PE. Use of scintigraphy for assessment of fracture healing and early diagnosis of osteomyelitis following fracture repair in rabbits. Am J Vet Res 2003;64:736-745.
7. Sonmezoglu K, Sonmezoglu M, Halac M, et al. Usefulness of 99mTc-ciprofloxacin (Infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy. J Nucl Med 2001;42:567-574.
8. Sarda L, Saleh-Mghir A, Peker C, Meulemans A, Cremieux AC, Le Guludec D. Evaluation of (99m)Tc-ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J Nucl Med 2002;43:239-245.
9. Sarda L, Cremieux AC, Lebellec Y, et al. Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 2003;44:920-926.
10. Malamitsi J, Giamarellou H, Kanellakopoulou K, et al. Infecton: a 99mTc-ciprofloxacin radiopharmaceutical for the detection of bone infection. Clin Microbiol Infect 2003;9:101-109.
11. Larikka MJ, Ahonen AK, Niemela O, et al. 99m Tc-ciprofloxacin (Infecton) imaging in the diagnosis of knee prosthesis infections. Nucl Med Commun 2002;23:167-170.
12. Larikka MJ, Ahonen AK, Niemela O, et al. Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun 2002;23:655-661.
13. Hall AV, Solanki KK, Vinjamuri S, Britton KE, Das SS. Evaluation of the efficacy of 99mTc-Infecton, a novel agent for detecting sites of infection. J Clin Pathol 1998;51:215-219.
14. Dumarey N, Blocklet D, Appelboom T, Tant L, Schoutens A. Infection is not specific for bacterial osteo-articular infective pathology. Eur J Nucl Med Mol Imaging 2002;29:530-535.
15. De Winter F, Gemmel F, Van Laere K, et al. 99mTc-ciprofloxacin planar and tomographic imaging for the diagnosis of infection in the postoperative spine: experience in 48 patients. Eur J Nucl Med Mol Imaging 2004;31:233-239.
16. Britton KE, Vinjamuri S, Hall AV, et al. Clinical evaluation of technetium-99m Infecton for the localisation of bacterial infection. Eur J Nucl Med 1997;24:553-556.
17. Britton KE, Wareham DW, Das SS, et al. Imaging bacterial infection with (99m)Tc-ciprofloxacin (Infecton). J Clin Pathol 2002; 55:817-823.
18. Hall AV. Investigation of a Novel Radiopharmaceutical, 99m Technetium Labelled Ciprofloxacin-99mTc-Infecton; Its In-Vitro Binding to Bacteria and Its Clinical Efficacy as an Imaging Agent in Infection [MRC Path dissertation]. London: St-Bartholomew's Hospital, 1996.
19. Solanki K. Imaging of Infections [US patent application]. London: British Technology Group, 1995.
20. Solanki KK, Bomanji J, Siraj Q, Small M, Britton KE. Tc-99m "Infecton" - a new class of radiopharmaceutical for imaging infection [abstract]. J Nucl Med 1993;34:119.
21. Oh SJ, Ryu JS, Shin JW, et al. Synthesis of 99mTc-ciprofloxacin by different methods and its biodistribution. Appl Radiat Isot 2002;57:193-200.
22. Dowling PM, Wilson RC, Tyler JW, Duran SH. Pharmacokinetics of ciprofloxacin in ponies. J Vet Pharmacol Ther 1995;18:7-12.
23. Ensink JM, van Klingeren B, Houwers DJ, Klein WR, Vulto AG. In-vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands. Equine Vet J 1993;25:309-313.
24. Lloyd JR, Cole JA, Macaskie LE. Reduction and removal of heptavalent technetium from solution by Escherichia coli. J Bacteriol 1997;179:2014-2021.
25. Ryu JK, Shin JW, Oh SJ, Cheon JH, Moon DH, Lee HK. Effect of ciprofloxacin pretreatment on 99mTc-ciprofloxacin (CIP) imaging of experimental bacterial infection [abstract]. J Nucl Med 2000; 41:322.
26. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. Am J Med 1987;82: 12-20.
27. Zeiler HJ. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth. Antimicrob Agents Chemother 1985;28: 524-527.
28. Zeiler HJ, Voigt WH. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. Am J Med 1987;82:87-90.
29. Alexander K. In Vitro Experimentation and Detection of Clinical Infections Using 99m-Tc-Ciprofloxacin [Master's thesis]. Columbus, Ohio: Ohio State University, 2004.
30. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update, 1994-1998. Drugs 1999;58:11-18.
31. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EK, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 2000;27:292-301.
32. Stathis VJ, Miller CM, Doerr GF, Coffey JL, Hladik WB 3rd. Effect of technetium Tc 99m pertechnetate on bacterial survival in solution. Am J Hosp Pharm 1983;40:634-637.